Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.02.07
- Author:
Yujie LIU
1
;
Panwen TIAN
1
Author Information
1. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Lung neoplasms;
Malignant pleural effusion
- MeSH:
Antineoplastic Agents;
therapeutic use;
Antineoplastic Agents, Immunological;
therapeutic use;
Carcinoma, Non-Small-Cell Lung;
complications;
pathology;
Humans;
Pleural Effusion, Malignant;
drug therapy;
Pleural Neoplasms;
drug therapy;
secondary
- From:
Chinese Journal of Lung Cancer
2019;22(2):118-124
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most commonly diagnosed cancer worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer seriously affect the patients' quality of life and prognosis. The management of MPE includes thoracentesis, pleurodesis, indwelling pleural catheters and drug perfusion in pleural cavity. Vascular endothelial growth factor (VEGF) and its receptor are a group of important ligands and receptors that affect angiogenesis. They are the main factors controlling angiogenesis, and they play an important role in the formation of MPE. Bevacizumab is a recombinant humanized VEGF monoclonal antibody, competitively binding to endogenous VEGF receptor. Bevacizumab can inhibit new blood vessel formation, reduce vascular permeability, prevent pleural effusion accumulation and slow the growth of cancers. This review aims to discuss the progress of bevacizumab in the treatment of MPE caused by non-small cell lung cancer (NSCLC), and explore the clinical application, efficacy, safety and future direction of bevacizumab.
.
